Australia's most trusted
source of pharma news
Posted 20 December 2021 AM
More than half of the new listing requests submitted to the PBAC's last big meeting of 2021 have been recommended, according to the November outcomes released late last Friday.
Both Dr Falk Pharma's Jorveza and Eusa Pharma's Sylvant - the two therapies resubmitted via the early re-entry pathway - were recommended by the committee, again suggesting the new system could be working.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.